Docetaxel Mylan

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
12-03-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
12-03-2015
Public Assessment Report Public Assessment Report (PAR)
12-03-2015

Active ingredient:

доцетаксел

Available from:

Mylan S.A.S.

ATC code:

L01CD02

INN (International Name):

docetaxel

Therapeutic group:

Антинеопластични средства

Therapeutic area:

Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms

Therapeutic indications:

Лечение на рак на гърдата, специални форми на рак на белия дроб (недребноклетъчен рак на белия дроб), рак на простатата, рак на стомаха или рак на главата и шията.

Product summary:

Revision: 6

Authorization status:

Отменено

Authorization date:

2012-01-31

Patient Information leaflet

                                142
Б. ЛИСТОВКА
Лекарствен продукт, който вече не е
разрешен за употреба
143
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
DOCETAXEL MYLAN 20 MG/1ML КОНЦЕНТРАТ ЗА
ИНФУЗИОНЕН РАЗТВОР
Доцетаксел (Docetaxel)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА,
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
болничния
фармацевт.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете вашия
лекар, болничен
фармацевт или медицинска сестра. Това
включва и всички възможни нежелани
реакции,
неописани в тази листовка. Вижте точка
4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА:
1.
Какво представлява Docetaxel Mylan 20 mg/1ml и за
какво се използва
2.
Какво е необходимо да знаете преди да
приемете Docetaxel Mylan 20 mg/1ml
3.
Как да приемате Docetaxel Mylan 20 mg/1ml
4.
Възможни нежелани реакции
5.
Как да съхранявате Docetaxel Mylan 20 mg/1ml
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА DOCETAXEL MYLAN 20 MG/1ML И ЗА
КАКВО СЕ ИЗПОЛЗВА
Доцетаксел е вещество извличано от
игличките на тисово дърво.
Доцетаксел принадлежи към група
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не е
разрешен за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Docetaxel Mylan 20 mg/1 ml концентрат за
инфузионен разтвор.
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Един ml концентрат за инфузионен
разтвор съдържа 20 mg доцетаксел
безводен (docetaxel
anhydrous).
Един флакон от 1 ml концентрат за
инфузионен разтвор съдържа 20 mg
доцетаксел.
Помощни вещества с известно действие:
Един ml концентрат за инфузионен
разтвор съдържа 395 mg етанол, безводен.
Един флакон от 1 ml концентрат за
инфузионен разтвор съдържа 395 mg
етанол, безводен.
За пълният списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Концентрат за инфузионен разтвор
(стерилен концентрат).
Концентратът е бледожълт до
кафеникавожълт разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Рак на гърдата
Docetaxel Mylan в комбинация с доксорубицин и
циклофосфамид е показан за адювантно
лечение на пациентки с:

операбилен рак на гърдата със
засягане на лимфните възли

операбилен рак на гърдата без
засягане на лимфните възли
За пациентки с операбилен рак на
гърдата без засягане на лимфните
възли, адювантната тер
                                
                                Read the complete document

Similar products

Active ingredient доцетаксел

доцетаксел

ATC code L01CD02

L01CD02

Marketed by Mylan S.A.S.

Mylan S.A.S.

INN (International Name) docetaxel

docetaxel

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 12-03-2015
Summary of Product characteristics Summary of Product characteristics Spanish 12-03-2015
Public Assessment Report Public Assessment Report Spanish 12-03-2015
Patient Information leaflet Patient Information leaflet Czech 12-03-2015
Summary of Product characteristics Summary of Product characteristics Czech 12-03-2015
Public Assessment Report Public Assessment Report Czech 12-03-2015
Patient Information leaflet Patient Information leaflet Danish 12-03-2015
Summary of Product characteristics Summary of Product characteristics Danish 12-03-2015
Public Assessment Report Public Assessment Report Danish 12-03-2015
Patient Information leaflet Patient Information leaflet German 12-03-2015
Summary of Product characteristics Summary of Product characteristics German 12-03-2015
Public Assessment Report Public Assessment Report German 12-03-2015
Patient Information leaflet Patient Information leaflet Estonian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Estonian 12-03-2015
Public Assessment Report Public Assessment Report Estonian 12-03-2015
Patient Information leaflet Patient Information leaflet Greek 12-03-2015
Summary of Product characteristics Summary of Product characteristics Greek 12-03-2015
Public Assessment Report Public Assessment Report Greek 12-03-2015
Patient Information leaflet Patient Information leaflet English 12-03-2015
Summary of Product characteristics Summary of Product characteristics English 12-03-2015
Public Assessment Report Public Assessment Report English 12-03-2015
Patient Information leaflet Patient Information leaflet French 12-03-2015
Summary of Product characteristics Summary of Product characteristics French 12-03-2015
Public Assessment Report Public Assessment Report French 12-03-2015
Patient Information leaflet Patient Information leaflet Italian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Italian 12-03-2015
Public Assessment Report Public Assessment Report Italian 12-03-2015
Patient Information leaflet Patient Information leaflet Latvian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Latvian 12-03-2015
Public Assessment Report Public Assessment Report Latvian 12-03-2015
Patient Information leaflet Patient Information leaflet Lithuanian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-03-2015
Public Assessment Report Public Assessment Report Lithuanian 12-03-2015
Patient Information leaflet Patient Information leaflet Hungarian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 12-03-2015
Public Assessment Report Public Assessment Report Hungarian 12-03-2015
Patient Information leaflet Patient Information leaflet Maltese 12-03-2015
Summary of Product characteristics Summary of Product characteristics Maltese 12-03-2015
Public Assessment Report Public Assessment Report Maltese 12-03-2015
Patient Information leaflet Patient Information leaflet Dutch 12-03-2015
Summary of Product characteristics Summary of Product characteristics Dutch 12-03-2015
Public Assessment Report Public Assessment Report Dutch 12-03-2015
Patient Information leaflet Patient Information leaflet Polish 12-03-2015
Summary of Product characteristics Summary of Product characteristics Polish 12-03-2015
Public Assessment Report Public Assessment Report Polish 12-03-2015
Patient Information leaflet Patient Information leaflet Portuguese 12-03-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 12-03-2015
Public Assessment Report Public Assessment Report Portuguese 12-03-2015
Patient Information leaflet Patient Information leaflet Romanian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Romanian 12-03-2015
Public Assessment Report Public Assessment Report Romanian 12-03-2015
Patient Information leaflet Patient Information leaflet Slovak 12-03-2015
Summary of Product characteristics Summary of Product characteristics Slovak 12-03-2015
Public Assessment Report Public Assessment Report Slovak 12-03-2015
Patient Information leaflet Patient Information leaflet Slovenian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 12-03-2015
Public Assessment Report Public Assessment Report Slovenian 12-03-2015
Patient Information leaflet Patient Information leaflet Finnish 12-03-2015
Summary of Product characteristics Summary of Product characteristics Finnish 12-03-2015
Public Assessment Report Public Assessment Report Finnish 12-03-2015
Patient Information leaflet Patient Information leaflet Swedish 12-03-2015
Summary of Product characteristics Summary of Product characteristics Swedish 12-03-2015
Public Assessment Report Public Assessment Report Swedish 12-03-2015
Patient Information leaflet Patient Information leaflet Norwegian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 12-03-2015
Patient Information leaflet Patient Information leaflet Icelandic 12-03-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 12-03-2015
Patient Information leaflet Patient Information leaflet Croatian 12-03-2015
Summary of Product characteristics Summary of Product characteristics Croatian 12-03-2015

Search alerts related to this product

Alerts Docetaxel Mylan доцетаксел

Docetaxel Mylan доцетаксел

View documents history

Documents history Documents history

Docetaxel Mylan